| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Other Events
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions. |
| 16 Nov 2026 | 10-Q |
| 04 Sep 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Harnessing fibrosis, unleashing life Science Deck| September 2026 Copyright © 2026 Rein Therapeutics |
| 27 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 21, 2026, Rein Therapeutics, Inc. (“Company”) received a notice of delisting (the “Notice”) from the Nasdaq Stock Market, LLC. The Notice stated that the Company had fallen below compliance with respect to the continued listing... |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | 10-Q |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 21 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On July 20, 2026, Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, for the purposes of: |
| 14 Jul 2026 | SCHEDULE 13G/A |
| 08 Jun 2026 | ARS |
| 08 Jun 2026 | DEFA14A |
| 08 Jun 2026 |
Proxy statement: annual meeting on July 20, 2026
CEO pay $883K, down 50% · say-on-pay vote |
| 28 May 2026 |
Form 4: Von Rickenbach Josef H, Director
Bought 3,420 shares ($3.56K) · Bought 15,950 shares ($16.7K) · Bought 23,190 shares ($24.5K) · 1 more |
| 28 May 2026 | PRE 14A |
| 15 May 2026 | 10-Q |
| 13 May 2026 |
Form 4: Windsor James Brian, Director
Bought 25,000 shares ($25K) · Disposed of 150,000 Stock Option (Right to Buy) (Grant/Award Acquisition) |
| 08 May 2026 | SCHEDULE 13G/A |
| 08 May 2026 | SCHEDULE 13G |
| 07 May 2026 | SCHEDULE 13G |
Loading...